German Hepatitis C-Registry (DHC-R)

Trial Profile

German Hepatitis C-Registry (DHC-R)

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 10 Nov 2017

At a glance

  • Drugs Boceprevir (Primary) ; Daclatasvir (Primary) ; Dasabuvir (Primary) ; Elbasvir/grazoprevir (Primary) ; Ledipasvir/sofosbuvir (Primary) ; Ombitasvir (Primary) ; Paritaprevir (Primary) ; Peginterferon alfa-2a (Primary) ; Peginterferon alfa-2b (Primary) ; Ribavirin (Primary) ; Simeprevir (Primary) ; Sofosbuvir (Primary) ; Telaprevir (Primary)
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Nov 2017 Results published in the Journal of Hepatology
    • 24 Oct 2017 Preliminary results presented at The Liver Meeting 2017: 68th Annual Meeting of the American Association for the Study of Liver Diseases
    • 03 Oct 2017 According to a Merck AG media release, data from this trial will be presented at The Liver Meeting 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top